Hypertension effective treatment coverage (controlled hypertension) in Sur
Sur: Hypertension effective treatment coverage (controlled hypertension) was 21.1% in 2019. ▲ Rising
Hypertension effective treatment coverage (controlled hypertension) in Sur, 1990–2019
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for hypertension effective treatment coverage (controlled hypertension) in Sur is 21.1%, measured in 2019. That is the highest value across all 30 years on record.
Compared with earlier readings it is up 1.9% on the previous year and up 24.1% over ten years.
Over the whole period, hypertension effective treatment coverage (controlled hypertension) in Sur peaked at 21.1% in 2019 and was at its lowest, 5.7%, in 1990.
The long-run direction has been consistently rising across the 30 years of available data.
Hypertension effective treatment coverage (controlled hypertension) in Sur, year by year
| Year | Value | Change |
|---|---|---|
| 1990 | 5.7% | — |
| 1991 | 5.9% | +3.5% |
| 1992 | 6.2% | +5.1% |
| 1993 | 6.5% | +4.8% |
| 1994 | 6.8% | +4.6% |
| 1995 | 7.2% | +5.9% |
| 1996 | 7.7% | +6.9% |
| 1997 | 8.2% | +6.5% |
| 1998 | 8.8% | +7.3% |
| 1999 | 9.4% | +6.8% |
| 2000 | 10.0% | +6.4% |
| 2001 | 10.7% | +7.0% |
| 2002 | 11.5% | +7.5% |
| 2003 | 12.3% | +7.0% |
| 2004 | 13.1% | +6.5% |
| 2005 | 14.0% | +6.9% |
| 2006 | 14.8% | +5.7% |
| 2007 | 15.6% | +5.4% |
| 2008 | 16.3% | +4.5% |
| 2009 | 17.0% | +4.3% |
| 2010 | 17.7% | +4.1% |
| 2011 | 18.3% | +3.4% |
| 2012 | 18.8% | +2.7% |
| 2013 | 19.3% | +2.7% |
| 2014 | 19.7% | +2.1% |
| 2015 | 20.0% | +1.5% |
| 2016 | 20.2% | +1.0% |
| 2017 | 20.5% | +1.5% |
| 2018 | 20.7% | +1.0% |
| 2019 | 21.1% | +1.9% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 7.2% | 5.7% | 9.4% | 10 |
| 2000s | 13.5% | 10.0% | 17.0% | 10 |
| 2010s | 19.6% | 17.7% | 21.1% | 10 |
Countries ranked near Sur
- 1 Canada 60.7% compare
- 2 South Korea 52.6% compare
- 3 Iceland 51.8% compare
- 4 Costa Rica 49.7% compare
More health data for Sur
- Pertussis - number of reported cases, gaps filled 8 (2025)
- Measles - number of reported cases, gaps filled 0 (2025)
- Total tetanus - number of reported cases, gaps filled 0 (2025)
- Diphtheria - number of reported cases, gaps filled 0 (2025)
- Measles - number of reported cases, annual growth rate -100 % change on previous year (1991)
- Pertussis - number of reported cases, annual growth rate -100 % change on previous year (2023)
- Total tetanus - number of reported cases, annual growth rate -100 % change on previous year (2021)
- Pertussis - number of reported cases 8 (2025)
- Total tetanus - number of reported cases 0 (2025)
- Diphtheria - number of reported cases 0 (2025)
Frequently asked questions
- What is hypertension effective treatment coverage (controlled hypertension) in Sur?
- Hypertension effective treatment coverage (controlled hypertension) in Sur was 21.1% in 2019, according to World Health Organization, Global Health Observatory.
- What is the highest hypertension effective treatment coverage (controlled hypertension) recorded in Sur?
- The highest recorded value was 21.1% in 2019.
- What is the lowest hypertension effective treatment coverage (controlled hypertension) recorded in Sur?
- The lowest recorded value was 5.7% in 1990.
- How does Sur rank for hypertension effective treatment coverage (controlled hypertension)?
- Sur ranks 1st out of 1 regions with data for 2019.
- Is hypertension effective treatment coverage (controlled hypertension) rising or falling in Sur?
- Over the last ten years it is up 24.1%. The long-run trend across the full record is rising.
- Where does this Sur data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Hypertension effective treatment coverage (controlled hypertension )among adults aged 30-79, age-standardized (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 30 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).